Skip to main content
Log in

In vivo and in vitro kinetics of mofarotene in mouse, rat, dog and man

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

The pharmacokinetics of mofarotene were investigated in mice, rats and dogs following single intravenous and oral administrations. Healthy volunteers were also given a single oral dose of 300 mg mofarotene. The data indicate a similar disposition for mofarotene in all species studied: low clearance consistent with a high bioavailability following oral dosing, and large volume of distribution indicating an extensive tissue uptake. Also in vitro in liver microsomes, the values for intrinsic clearance were in all species within a 2-fold range. The dog, however, tended to exhibit, both in vitro and in vivo, the lowest clearance. Although (due to the lack of protein binding data) a direct prediction of the in vivo clearance from in vitro data was not possible, the experiments with liver microsomes did provide a clear insight into the rate of elimination of mofarotene in vivo in the different species studied including man.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Eliason J., Teelmann K., Crettaz M. (1990): New retinoids and the future of retinoids in skin cancer. In: Marks R. (Ed) Retinoids in cutaneous malignancy. Oxford, Blackwell, pp. 157–170.

    Google Scholar 

  2. Hartmann D., Eliason J., Teelmann K., Kaufmann F., Klaus M. (1993): Ro 40-8757, a novel arotinoid with anti-cancer activity. In: Livrea M.A., Packer L. (Eds) Retinoids, progress in research and clinical applications. New York, Marcel Dekker.

    Google Scholar 

  3. Eliason J., Kaufmann F., Tanaka T., Tsukaguchi T. (1993): Anti-proliferative effects of the arotinoid Ro 40-8757 on human cancer cell lines in vitro. Br. J. Cancer, 67, 1293–1298.

    CAS  PubMed  Google Scholar 

  4. Ba B., Coassolo Ph. (1991): Personal communication.

  5. Von Bahr C., Groth C.-G., Jansson H., Lundgren G., Lind M., Glaumann H. (1980): Drug metabolism in human liver in vitro: establishment of a human liver bank. Clin. Pharmacol. Ther., 27, 711–725.

    Article  Google Scholar 

  6. Omura T., Sato R. (1964): The carbon monoxide-binding pigment of liver microsomes. J. Biol. Chem., 239, 2379–2385.

    CAS  PubMed  Google Scholar 

  7. Smith P.K., Krohn R.I., Hermanson G.T., et al. (1985): Measurement of protein binding using bicinchronic acid. Anal. Biochem., 150, 76–85.

    Article  CAS  PubMed  Google Scholar 

  8. Boxenbaum H. (1980): Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. J. Pharmacokinet. Biopharm., 8, 165–176.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vallès, B., Ba, B., Wyss, R. et al. In vivo and in vitro kinetics of mofarotene in mouse, rat, dog and man. Eur. J. Drug Metab. Pharmacokinet. 20, 49–53 (1995). https://doi.org/10.1007/BF03192288

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03192288

Keywords

Navigation